LY3475766 / Eli Lilly - LARVOL DELTA

Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial. (PubMed, Nat Med) - P1 | "LY3475766 thus significantly reduced atherogenic lipoprotein levels while increasing HDL-C levels; however, the effects on cardiovascular risk remain to be established. ClinicalTrials.gov registration: NCT04052594 ."

Journal • P1 data • Cardiovascular • Dyslipidemia • Metabolic Disorders • Mixed Hyperlipidemia • ANGPTL3 • APOB • LPL

A Study of LY3475766 in Healthy Participants (clinicaltrials.gov) - P1; N=48; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Completed; N=70 ➔ 48

Clinical • Enrollment change • Trial completion • Dyslipidemia • Metabolic Disorders • APOB

A Study of LY3475766 in Healthy Participants (clinicaltrials.gov) - P1; N=70; Active, not recruiting; Sponsor: Eli Lilly and Company; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Dyslipidemia • Metabolic Disorders • APOB

A Study of LY3475766 in Healthy Participants (clinicaltrials.gov) - P1; N=55; Recruiting; Sponsor: Eli Lilly and Company; Suspended ➔ Recruiting

Clinical • Enrollment open • Dyslipidemia • APOB

A Study of LY3475766 in Healthy Participants (clinicaltrials.gov) - P1; N=55; Suspended; Sponsor: Eli Lilly and Company; Trial completion date: Nov 2020 ➔ Mar 2021; Trial primary completion date: Nov 2020 ➔ Mar 2021

Clinical • Trial completion date • Trial primary completion date • Dyslipidemia • APOB

A Study of LY3475766 in Healthy Participants (clinicaltrials.gov) - P1; N=55; Suspended; Sponsor: Eli Lilly and Company; Trial completion date: Aug 2020 ➔ Nov 2020; Recruiting ➔ Suspended; Trial primary completion date: Aug 2020 ➔ Nov 2020

Clinical • Trial completion date • Trial primary completion date • Trial suspension • Cardiovascular • Dyslipidemia • APOB

A Study of LY3475766 in Healthy Participants (clinicaltrials.gov) - P1; N=55; Recruiting; Sponsor: Eli Lilly and Company; N=97 ➔ 55

Clinical • Enrollment change • APOB

A Study of LY3475766 in Healthy Participants (clinicaltrials.gov) - P1; N=97; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open